Kornimate/medical-research-clean huggingface dataset:
extracapsular supradiscal subperiosteal surgical procedure for temporomandibular joint internal derangement correction: novel technique

Conditions: TMJ Internal Derangement; TMJ - Dislocation of Temporomandibular Joint; TMJ - Oral &amp;amp;Maxillofacial Surgery

Summary: this study aims to evaluate the efficacy of the ess technique in correcting tmj internal derangement, with a focus on functional outcomes and patient satisfaction.

background: internal derangement (id) of the temporomandibular joint (tmj) is a prevalent condition characterized by disc displacement, leading to pain, restricted mandibular mobility, and reduced quality of life. while non-surgical treatments are often the first line of management, surgical intervention becomes necessary in refractory cases. traditional surgical methods, such as arthrocentesis and disc repositioning, have shown variable success rates, particularly in advanced stages of disc damage. this study introduces the extracapsular supradiscal subperiosteal (ess) surgical procedure, a novel technique designed to address these limitations. therefore, current study aims to evaluate the efficacy of the ess technique in correcting tmj internal derangement, with a focus on functional outcomes and patient satisfaction. patients and methods: a prospective study was conducted on 50 patients (47 females, 3 males; age range: 11-50 years) with tmj id refractory to non-surgical management. the ess procedure was performed to reposition the displaced disc and stabilize retrodiscal tissues without violating the joint capsule. preoperative and postoperative assessments included pain levels, maximum mouth opening (mmo), and subjective patient feedback.

Eligibility criteria:
inclusion criteria: * patients with stage 3 or stage 4 internal derangements of tmj radiological and clinical findings should coincide to set up the diagnosis and predict the treatment plan. exclusion criteria: * age less than 11 years old * age more than 50 years are excluded

Keywords: tmj tmj derangement extracapsular surgery supradiscal subperiosteal technique facial plastic surgery
a study of oral l-citrulline in sickle cell disease

Conditions: Sickle Cell Disease

Summary: sickle cell disease is a genetic red blood cell disorder that can result in blocking of the small blood vessels from sickle shaped red blood cells. this causes pain, the main feature of sickle cell disease. also, low amounts of nitric oxide can occur in sickle cell disease, a substance important for widening the blood vessel wall and therefore preventing blockage of the small blood vessels. citrulline is a drug that is known to increase nitric oxide. this is a phase i study of citrulline given by mouth to evaluate the safety, tolerability and appropriate dosing of this medication for individuals with sickle cell disease.


Eligibility criteria:
inclusion criteria: 1. sickle cell disease genotypes (hbss, hbs/β-thalassemia 2. hbs/β+thalassemia, hbsc) 3. patients with sickle cell disease aged 10 to 25 years old 4. patients ages 10 through 17 years of age, whose parents have signed permission, and who provide signed patient assent themselves 5. patients 18 through 25 years of age who provide signed consent. exclusion criteria: 1. presence of any acute illness defined by fever \>100.4°f within the past 48 hours 2. presence of sickle cell pain crisis defined by the presence of pain requiring oral or parental opioid therapy. 3. presence of acute chest syndrome or presence of any other complication related to sickle cell disease requiring hospitalization such as splenic sequestration, hepatic sequestration, stroke, avascular necrosis of the hip/shoulder, acute priapism, and patients with diabetes etc. 4. severe anemia (hemoglobin \< 5g/dl) 5. history of red blood cell transfusion within the last 14 days 6. systemic steroid therapy within the last 48 hours 7. pregnant (as confirmed by a negative urine pregnancy test) or lactating female 8. alanine/aspartate transferase \>2x upper limit of normal laboratory range for age. 9. elevated serum creatinine: age 6 to 13 years \> 0.9 mg/dl, age 14-17 years 1.0 mg/dl, age \>18 years \>1.5mg/dl 10. patients with an inability to give assent (ages 10 to 17 years) or consent (ages 18 through 25 years) will be excluded 11. history of diabetes due to risk of electrolyte imbalance
lactobacillus reuteri supplementation in the treatment of infantile colic

Conditions: Infantile Colic

Summary: the purpose of this study is to evaluate the efficacy of the oral administration of lactobacillus reuteri in treating infantile colic as defined by the rome iii criteria. forty breastfed infants aged from 29 days to 3 months will be enrolled and blinded randomized to receive orally l.reuteri or placebo. the rate of responders (reduction of daily crying time \>50% compared to the baseline) will be assessed at day 7, day 14 and day 21 in both groups. the average daily crying time as well as the associated digestive symptoms will also be analyzed.

note: the study never started.

Eligibility criteria:
inclusion criteria: 1. exclusively breastfed infants 2. infant aged of 29 days to 3 months 3. with a diagnosis of infantile colic as defined by the rome iii criteria 4. birth at term and eutrophic (weight, height, head circumference) 5. apgar score\> 7 at 5 minutes 6. consent to the study signed by the two parents. 7. availability during the study period exclusion criteria: 1. associated severe chronic disease 2. acute infectious disease 3. personal or family first degree history of allergy to milk proteins 4. several infants of the same family from a multiple pregnancy 5. infants who received antibiotics one week prior to randomization 6. infants who received probiotics one week prior to randomization 7. mother who received antibiotics 1 week before randomization 8. regular consumption of probiotics by the mother 1 week before randomization 9. infants-included in another clinical study 10. lack of insurance coverage by the french social security 11. non exclusively breastfed infants

Keywords: pediatric gastroenterology probiotics lactobacillus reuteri
time restricted eating and innate immunity

Conditions: Time Restricted Feeding; Myocardial Infarction; Atherosclerotic Cardiovascular Disease

Summary: the goal of this cross over study is to investigate the effect of short term time restricted eating (tre) on the innate immune system in patients with a history of myocardial infarction.

in the recent years, research has shown the prominent role of low grade systemic inflammation in cardiovascular disease (cvd) and the crucial role myeloid cells, mainly monocytes and macrophages, play in atherogenesis. time restricted eating (tre), i.e. eating the normal amount of calories within a limited time period per day, has a beneficial effect on multiple factors involved in the development of cvd, such as blood pressure, heart rate, lipid and blood glucose levels, and insulin sensitivity. tre also reduces markers of systemic inflammation and reduces the number of circulating monocytes. it is now hypothesized that tre reduces the pro-inflammatory monocyte phenotype of patients with a history of myocardial infarction. therefore, the investigators will perform a exploratory prospective randomised open label blinded endpoint cross-over study to investigate the effect of short term tre on the innate immune system in patients with a history of myocardial infarction.

Eligibility criteria:
inclusion criteria: * adult (age \>18 years) * diagnosed with a myocardial infarction (between 1 and 5 years ago) * body mass index between 20 and 35 kg/m2 * able to understand, be motivated and follow the study related procedures * able to understand and give written informed consent exclusion criteria: * myocardial infarction (defined as an increase in cardiac enzymes in combination with symptoms of ischemia or newly developed ischemic ecg changes), coronary artery bypass graft surgery or other major (cardiovascular) surgery, stroke or transient ischemic attack (tia) in the past 1 year prior to screening. * use of immunomodulatory drugs * use of drugs that need to be taken with food. * diabetes mellitus type i and type ii * medical history of any disease associated with immune deficiency (either congenital or acquired, including chemotherapy, active malignancy, organ transplant) or auto immune disease * clinically significant infections within 1 months prior to start of or during intervention period or control period (defined as fever \>38.5). * vaccination \<1 month before start of or during intervention or control period. * eating disorders

Keywords: time restricted eating
the effect of the number of central lymph nodes on changes in parathyroid function

Conditions: Thyroid Cancer

Summary: this study collected data from patients who underwent thyroidectomy in the breast and thyroid surgery department of shandong provincial hospital from january 2020 to december 2023 by reviewing medical records. the main calculation indicator was the changes in pth before and after surgery. this study grouped patients based on the number of central lymph nodes under postoperative paraffin pathology, and statistically analyzed the changes and differences in pth before and after surgery in different groups to verify the relationship between the number of central lymph nodes in the thyroid gland and parathyroid function, and to provide reference for surgical selection in thyroid cancer patients with multiple cervical lymph node metastases.

the central lymph nodes of the thyroid gland refer to the lymph nodes located around the thyroid and trachea. the central lymph nodes are the primary site of thyroid cancer metastasis, and therefore play an important role in thyroid surgery. in thyroid surgery, preventive central lymph node dissection is a routine procedure, but during this process, the parathyroid gland may be impaired due to surgical injury or insufficient blood supply. hypothyroidism, also known as parathyroidism, is a common complication of thyroid surgery. when the parathyroid gland is accidentally injured or its blood supply is disrupted, it can lead to insufficient production of parathyroid hormone. parathyroid hormone is a key hormone that regulates blood calcium levels. insufficient levels can lead to hypocalcemia, manifested as hand and foot spasms, muscle spasms, and even arrhythmia. from a surgical perspective, the number of lymph nodes in the central region of the thyroid gland may affect the preservation and functional protection of the parathyroid gland. a large number of lymph nodes indicates that they may have a wider range of disease invasion, requiring more thorough lymph node dissection, thereby increasing the risk of damaging the parathyroid gland or its blood supply.

Eligibility criteria:
inclusion criteria: * all cases were the first to undergo thyroidectomy surgery. * all clinical data and research materials of the cases are complete. * all cases underwent thyroid function examination before and after surgery. * all cases underwent preoperative thyroid and neck lymph node examinations by the ultrasound department of shandong provincial hospital. exclusion criteria: * except for cases of recurrence. * cases with incomplete clinical data and research materials are excluded. * cases that have not undergone thyroid function tests before and after surgery are excluded. * excluding cases of secondary surgery. * cases that have not undergone thyroid and neck lymph node examinations by the ultrasound department of shandong provincial hospital before surgery are excluded.

Keywords: thyroid cancer central lymph nodes pth
cannabinoids for drug resistant epilepsy (dre) in adults and children

Conditions: Drug Resistant Epilepsy

Summary: epilepsy is a neurological disorder affecting more than 50 million people globally, including more than 260,000 canadians. cannabidiol (cbd) reduces seizure frequency and improves quality of life for adults and children with drug resistant epilepsy (dre). several uncontrolled, small, open label studies reported that cbd-enriched cannabis herbal extract (che) resulted in a reduction of seizure frequency, but we lack critical information on efficacy, comparative effectiveness and dosing of cbd and ∆9-tetrahydrocannabinol (thc) in children and adults with dre. can-dre is an early phase, triple-blind, placebo-controlled, randomized clinical trial to answer the questions of if cannabinoids work to reduce seizures in children and adults (24 months to 55 years) with dre and if cbd works better in an isolate or in a cbd-enriched cannabis herbal extract. the primary outcome of can-dre is reported monthly seizure count from baseline to maintenance phase.


Eligibility criteria:
inclusion criteria: 1. ages 24 months to 55 years old at the time of enrollment 2. diagnosed with dre: not achieved seizure freedom, with adequate trials of 2 antiseizure medications 29 3. medical history of 4 + clinically recognizable seizures (any type with clusters counted as a single event) per month 4. have a negative pregnancy test at screening for patients who have experienced menarche 5. agree to abstain from driving and recreational cannabis use throughout the study exclusion criteria: 1. diagnosis of psychogenic non-epileptic seizure 2. recent (\<30 days) change in anticonvulsant therapies including anticonvulsant medications, or settings on vagal nerve stimulator 3. ketogenic diet started within 6 months (participants stable on the ketogenic diet for more than 6 months are eligible to participate) 4. vagal nerve stimulator implanted and activated within 12 months 5. concomitant regular use of narcotics (except in emergencies and physician supervised) 6. initiation or dosage change of oral or injected steroids within 3 months 7. allergy or intolerance to compounds in trial preparations 8. dre secondary to progressive neurological disease 9. clinically significant cardiac, renal or hepatic disease (as assessed by site investigator); elevated liver enzymes (ggt and/or ast and/or alt) or lipase \>3 times upper limit, adjusted for age 10. history of psychotic disorders 11. uncontrolled (in the perspective of the qualified investigator) medical conditions including substance use disorders 12. history or concurrent cannabis use disorder 13. unwilling or unable to use highly effective methods of contraception throughout the study period and three months post-trial, where applicable

Keywords: adult and children cannabis dre cbd-isolate cbd-enriched cannabis herbal extract (che) cannabidiol
health and faith working to control blood pressure

Conditions: Hypertension

Summary: faith community nursing programs have grown out of churches as a response to the inequity of healthcare delivery to uninsured and underinsured communities. these programs provide outreach to community members and extend their services beyond just the parishioners of the churches, reaching more uninsured people than traditional medical services. although faith community nursing programs have been established throughout the united states, no evaluation of these programs has been done. queenscare is taking the lead in measuring the effect of parish nurses on health outcomes. in this project we have one specific aim: to measure the effect of parish nurse visits on blood pressure control on community-dwelling hypertensive patients. our study will involve recruiting hypertensive patients from parish nurse led health fairs and interviewing subjects at the time of recruitment. patients will either be randomized to parish nurse visits or primary care physician appointments. we will have a 4-month follow-up period with a re-check of blood pressures and an exit interview of the patient. from this study, we hope to better understand if parish nurse visits improve blood pressure and medication compliance among hypertensive patients.


Eligibility criteria:
inclusion criteria: * we will be including adults who are 18 years and older who have attended a health fair or screening event at one of queenscare health and faith partnership parish nurse sponsored church events in los angeles. * patients must be either english or spanish speaking. * patients will be enrolled by blood pressure readings at the screening event. we will be using the jnc 71 criteria for diagnosing hypertension. * patients with blood pressures above 140/90 will be defined as hypertensive. * diagnosed and previously undiagnosed hypertensive patients will be included in the study. * the patient must also be able to come to the follow-up appointment in 4 months. exclusion criteria: * pregnant women will not be included in the study. * patients who do not speak english or spanish will be excluded from the study since we do not have the capacity to translate all our materials into multiple languages. * those deemed by the research assistant to be incapable to give informed consent (due to intoxication, dementia, or other causes) will also be excluded from the study. * patients younger than 18 years old will be excluded from the study. * patients who have seen a parish nurse in her office hours in the past 6 months will be excluded from the study. we do not want patients who have an already established relationship with a parish nurse to be enrolled in the study with the chance of being randomized to the physician-only arm, which would interrupt the continuity of care the patient is receiving from the parish nurse.

Keywords: hypertension parish nurse
a study to evaluate the safety, tolerability, and exploratory efficacy of ims001 in subjects with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this is a phase 1 study of ims001, given as a single dose to subjects with multiple sclerosis who experience inadequate response and/or intolerability to disease modifying treatments. ims001 is a human embryonic cell derived (hesc) mesenchymal stem cell (msc). mscs have the potential to modulate disease course.


Eligibility criteria:
inclusion criteria: * provides signed and dated informed consent in accordance with local regulations. * 18 to 65 years of age. * diagnosis of ms. * has had an inadequate response dmts. * edss within protocol parameters. * able and willing to undergo mris. * must be clinically stable for 1 month prior to day 1. exclusion criteria: * has a known or suspected hypersensitivity to human serum albumin, diphenhydramine, acetaminophen, methylprednisolone, or any of the components of ims001. * has history of excluded medications, per protocol, prior to day 1. * has a history of neoplastic disease except for basal cell carcinoma, non-metastatic squamous cell carcinoma of the skin that has been excised with clean margins, or adequately treated in-situ carcinoma of the cervix. * prior history of any other autoimmune disease, myelodysplasia, or hematologic disease. * prior treatment with any allogeneic cell therapy or tissue transplant. * prior history of smoking equivalent to ˃20 cumulative pack years of cigarettes. * recent clinically significant infection during the screening phase. * has any medical or psychiatric condition that would impact outcome or participation in the study. * has clinically significant abnormal findings on the electrocardiogram (ecg) during the screening phase. * has known or documented human immunodeficiency virus (hiv) infection or active hepatitis b, or c. * has an elevated liver function test abnormality during the screening phase. * has abnormalities of blood count during the screening phase. * has laboratory abnormalities of renal function during the screening phase. * has other clinically significant laboratory abnormalities during screening phase. * body weight ≥120 kg. * women pregnant, breast feeding, or planning to become pregnant during the study. * is unavailable for the duration of the trial, is likely to be noncompliant with the protocol, or is generally felt to be unsuitable by the principal investigator. * current or recent participation in any other clinical or device trials within 3 months prior to day 1.
a first time in man study to asses the safety and tolerability of azd7624 in healthy subjects

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: this is a first in human study to assess the safety and tolerability of azd7624, following inhaled administration of single ascending doses in healthy male volunteers and female volunteers of non-child bearing potential. pharmacokinetics (what the body does to the drug) and pharmacodynamic (what the drug does to the body) parameters will be also assessed as secondary objectives.

a double-blind placebo-controlled, randomised, single centre, first time in man study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending inhaled doses of azd7624 in healthy subjects

Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects aged 18 to 55 years * able to inhale from the spira nebuliser according to the provided instructions * females must have a negative pregnancy test at screening and on admission (day 1) to the cpu, must not be lactating and must be of non-childbearing potential. * body mass index (bmi) between 18 and 30 kg/m2 inclusive and weighing at least 50 kg and no more than 100 kg inclusive. * fev1 \>80% of the predicted normal value. exclusion criteria: * history of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to azd7624 * history of any clinically important disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study * history or family history of muscle diseases * known or suspected history of drug abuse as judged by the investigator * use of any prescribed or non-prescribed medication including antacids, analgesics other than paracetamol/acetaminophen, herbal remedies, vitamins (excluding routine vitamins but including megadose \[intake of 20 to 600 times the recommended daily dose\])

Keywords: phase 1 healthy volunteers single ascending dose (sad) first time in man pharmacokinetics pharmacodynamics
identifiable factors that may lead to postoperative nausea and vomiting after simple laparoscopic appendectomy

Conditions: Acute Appendicitis

Summary: this is a retrospective chart review meant to identify any factors that are correlated with and may possibly lead to postoperative nausea and vomiting in order to predict need for longer hospital stays and potentially decrease postoperative nausea and vomiting.


Eligibility criteria:
inclusion criteria: * laparoscopic simple appendectomy * uncomplicated surgery exclusion criteria: * none